The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joo, Moon Kyung | - |
dc.contributor.author | Park, Jong-Jae | - |
dc.contributor.author | Lee, Beom Jae | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Bak, Young-Tae | - |
dc.date.accessioned | 2021-09-06T03:02:22Z | - |
dc.date.available | 2021-09-06T03:02:22Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-04 | - |
dc.identifier.issn | 1791-2997 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103616 | - |
dc.description.abstract | Recent studies revealed that long-term intake of proton pump inhibitor (PPI) increases the risk of vertebral or hip fracture; however, the exact mechanism for this is not known. To evaluate the effect of long-term PPI therapy on bone turnover, we analyzed the signaling pathway involved in osteoclast differentiation and bone resorption/formation markers using ovariectomized rats. Six-week-old Sprague-Dawley (S-D) rats were ovariectomized, and two weeks later they were divided into four groups (group A, normal diet + placebo; group B, low calcium diet + placebo; group C, normal diet + PPI; and group D, low calcium diet + PPI). Omeprazole, at a concentration of 30 mg/kg, was administered orally for eight weeks and the rats were sacrificed when they were 16 weeks old. The relative expression levels of the receptor activator of NF-kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio, c-Fos, nuclear factor of activated T cells c1 (NFATc1) and osteocalcin in femoral bone marrow cells were compared, and serum C-terminal cross-linking telopeptide of type I (CTX-1) levels were determined. The relative ratio of RANKL/OPG was increased in group D, and gene expression levels of c-Fos and NFATc1 were upregulated in groups B and D, which are involved in differentiation and activation of osteoclasts. Furthermore, expression levels of osteocalcin, a bone formation marker, were decreased and levels of serum CTX-1, a bone resorption marker, were increased in group D. Taken together, a low calcium diet and PPI administration are thought to collaborate in order to alter osteoclast activity and bone resorption signaling. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | B LIGAND RANKL | - |
dc.subject | OSTEOCLAST DIFFERENTIATION | - |
dc.subject | RECEPTOR ACTIVATOR | - |
dc.subject | REFLUX DISEASE | - |
dc.subject | NUCLEAR-FACTOR | - |
dc.subject | C-FOS | - |
dc.subject | OMEPRAZOLE | - |
dc.subject | GUIDELINES | - |
dc.subject | RESORPTION | - |
dc.subject | THERAPY | - |
dc.title | The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Joo, Moon Kyung | - |
dc.contributor.affiliatedAuthor | Park, Jong-Jae | - |
dc.contributor.affiliatedAuthor | Lee, Beom Jae | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.contributor.affiliatedAuthor | Bak, Young-Tae | - |
dc.identifier.doi | 10.3892/mmr.2013.1327 | - |
dc.identifier.scopusid | 2-s2.0-84875251798 | - |
dc.identifier.wosid | 000321467100034 | - |
dc.identifier.bibliographicCitation | MOLECULAR MEDICINE REPORTS, v.7, no.4, pp.1267 - 1272 | - |
dc.relation.isPartOf | MOLECULAR MEDICINE REPORTS | - |
dc.citation.title | MOLECULAR MEDICINE REPORTS | - |
dc.citation.volume | 7 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1267 | - |
dc.citation.endPage | 1272 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | B LIGAND RANKL | - |
dc.subject.keywordPlus | OSTEOCLAST DIFFERENTIATION | - |
dc.subject.keywordPlus | RECEPTOR ACTIVATOR | - |
dc.subject.keywordPlus | REFLUX DISEASE | - |
dc.subject.keywordPlus | NUCLEAR-FACTOR | - |
dc.subject.keywordPlus | C-FOS | - |
dc.subject.keywordPlus | OMEPRAZOLE | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | RESORPTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | proton pump inhibitor | - |
dc.subject.keywordAuthor | bone metabolism | - |
dc.subject.keywordAuthor | osteoclast | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.